Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for kids with rare liver tumors: tailored therapy trial shows promise

NCT ID NCT03017326

Disease control Sponsor: University of Birmingham Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests different treatment plans based on each child's risk level for two rare liver cancers: hepatoblastoma and hepatocellular carcinoma. About 450 children will receive chemotherapy and possibly surgery, with the goal of preventing the cancer from coming back. The approach aims to give the right amount of treatment to each child to improve outcomes while reducing side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 450 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2017

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

Up to 30 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Clinical diagnosis of HB\* and histologically defined diagnosis of HB or HCC. \*Histological confirmation of HB is required except in emergency situations where: * a) the patient meets all other eligibility criteria, but is too ill to undergo a biopsy safely, the patient may be enrolled without a biopsy. * b) there is anatomic or mechanical compromise of critical organ function by tumour (e.g., respiratory distress/failure, abdominal compartment syndrome, urinary obstruction, etc.) * c) Uncorrectable coagulopathy * Age ≤30 years * Written informed consent for trial entry Exclusion Criteria: * Any previous chemotherapy or currently receiving anti-cancer agents * Recurrent disease * Previously received a solid organ transplant; other than orthotopic liver transplantation (OLT). * Uncontrolled infection * Unable to follow or comply with the protocol for any reason * Second malignancy * Pregnant or breastfeeding women

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Carcinoma, hepatocellular are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hepatoblastoma hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Carcinoma, hepatocellular Hepatoblastoma

Contacts and locations

Locations

  • Addenbrooke's Hospital

    Cambridge, CB2 0QQ, United Kingdom

  • Alder Hey Children's Hospital

    Liverpool, L12 2AP, United Kingdom

  • Birmingham Children's Hospital

    Birmingham, B4 6NH, United Kingdom

  • Bristol Royal Hospital for Children

    Bristol, BS2 8BJ, United Kingdom

  • CHU de Rennes

    Rennes, 35033, France

  • Children's Health Ireland Crumlin

    Dublin, 12 N512, Ireland

  • Cliniques Universitaires Saint-Luc

    Brussels, Woluwe-Saint-Lambert, 1200, Belgium

  • Great North Children's Hospital

    Newcastle upon Tyne, NE1 4LP, United Kingdom

  • Great Ormond Street Hospital

    London, WC1N 3JH, United Kingdom

  • Hopitaux Universitaires de Geneve

    Geneva, CH 1211, Switzerland

  • Kuopio University Hospital

    Kuopio, FI20029 KYS, Finland

  • Leeds General Infirmary

    Leeds, LS1 3EX, United Kingdom

  • Leicester Royal Infirmary

    Leicester, LE1 5WW, United Kingdom

  • Ludwig-Maximillians-University Munich

    Munich, 80337 Munich, Germany

  • Medical University of Gdansk

    Gdansk, 80-803, Poland

  • Noah's Ark Children's Hospital for Wales

    Cardiff, CF14 4XW, United Kingdom

  • Nottingham Children's Hospital

    Nottingham, NG7 2UH, United Kingdom

  • Oslo University Hospital

    Nydalen, 0424 Oslo, Norway

  • Oxford Children's Hospital

    Oxford, OX3 9DU, United Kingdom

  • Prinses Maxima Center

    Utrecht, 3584 CS, Netherlands

  • Royal Aberdeen Children's Hospital

    Aberdeen, AB25 2ZG, United Kingdom

  • Royal Belfast Hospital for Sick Children

    Belfast, BT12 6BE, United Kingdom

  • Royal Hospital for Children

    Edinburgh, EH9 1LW, United Kingdom

  • Royal Hospital for Children

    Glasgow, G51 4TF, United Kingdom

  • Royal Manchester Children's Hospital

    Manchester, M13 9WL, United Kingdom

  • Schneider Children's Medical Center

    Petah Tikva, 4920235, Israel

  • Sheffield Children's Hospital

    Sheffield, S10 2TH, United Kingdom

  • St. Anna Kinderspital

    Vienna, 1090, Austria

  • The Royal Marsden Hospital

    Sutton, SM2 5PT, United Kingdom

  • University Hospital Motol

    Prague, 150 06 Prague 5, Czechia

  • University Hospital Reina Sofia

    Córdoba, 14004, Spain

  • University Hospital Southampton

    Southampton, SO16 6YD, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.